NET PROFIT (x1000 EUR)
EMPLOYEES
Oblique Therapeutics AB (publ)
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
5
|
183
|
27 |
| Earnings before taxes |
-5,581
|
-4,812
|
-6,027 |
| EBITDA |
-3,403
|
-4,334
|
-5,695 |
| Total assets |
1,673
|
1,633
|
3,015 |
| Current assets |
1,457
|
729
|
2,181 |
| Current liabilities |
552
|
1,012
|
934 |
| Equity capital |
1,044
|
302
|
1,929 |
| - share capital |
165
|
68
|
74 |
| Employees (average) |
18
|
18
|
16 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
62.4%
|
18.5%
|
64.0% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-333.3%
|
-283.5%
|
-199.0% |
| Current ratio |
263.9%
|
72.0%
|
233.5% |
| Return on equity (ROE) |
-534.6%
|
-1593.4%
|
-312.4% |
| Change turnover | |||
| Change turnover % | -100% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % |
13%
|
33% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.